Aagami has received contract extension from its US based client owing to their experience with us and progress seen.
The client’s Phase 2 drug could be a single drug to treat all three "tripledemic" viruses (COVID, RSV, FLU), something that has been an elusive target in the development of antiviral therapeutics.
Highlights of clients drug:
- First-in-class drug with Novel Mechanism of Action (MoA)
- Phase 1 Successfully completed. And shown strong activity in lethal animal model studies for MPOX and Smallpox treatment developments. Now in Phase II clinical trial stage.
- Applicable to multiple indications: RSV, Influenza, COVID and Long COVID, Smallpox/MPOX, Bird Flu, and Measles too.
- Demonstrated extremely broad antiviral spectrum of activity in animal models, which could prove to be as revolutionary for viral infections as penicillin was for bacterial infections. This broad spectrum is because the drug asset is designed to mimic a host-side feature that is used by over 90-95% of human pathogenic viruses when they cause infection.
- It’s Virus-Escape Resistant to the greatest possible degree, because the host-side SPG feature is invariant and is required by the virus for infection despite virus evolution. Moreover, viruses cannot escape the drug asset even as they evolve variants in the field, because of its broad-spectrum antiviral effect and the host-mimetic technology.
- In addition, the Company has developed a platform that enables important non-oral drugs to be delivered as active oral drugs, which we believe is a sought-after technology.
- The drug asset is based on the Novel, Host-Mimetic, Direct-Antiviral-Acting, “Re-Infection Blocking”, Patented Nanoviricide™ Technology Platform that is not reliant on the host immune system, making it very effective for drugs targeted towards geriatric and pediatric patients.
- The client also eyes role in US bird flu fight as USDA unveils $100M initiative
The overall market size of the indications addressed is estimated to be well in excess of $10 Billion. A lot of non-confidential material is available including in audio video format, including coverage by third parties.
Aagami is helping the client secure Licensing and partnering opportunities for its Phase 2 stage asset, and its key platform technology.
If you would like to know more, please contact us.